James Robert Krycer

James Robert Krycer

Auto-generated profile, based on publicly available information

James Robert Krycer

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, 4006, Australia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
JKJames R. Krycer
James R. Krycer
LSLaura J. Sharpe
Laura J. Sharpe
WLWinnie Luu
Winnie Luu
ABAndrew J. Brown
Andrew J. Brown

1 October 2016 in Cell Metabolism
Verified
Journal Article
Closed access
SSSamantha M. Solon-Biet
Samantha M. Solon-Biet
VCVictoria C. Cogger
Victoria C. Cogger
TPTamara Pulpitel
Tamara Pulpitel
MHMarika Heblinski
Marika Heblinski
DWDevin Wahl
Devin Wahl
SSStephen J. Simpson
Stephen J. Simpson

1 October 2019 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
DFDaniel Fazakerley
Daniel Fazakerley
JKJames R. Krycer
James R. Krycer
AKAlison L. Kearney
Alison L. Kearney
SHSamantha L. Hocking
Samantha L. Hocking
DJDavid E. James
David E. James
Daniel J. Fazakerley, James R. Krycer, Alison L. Kearney, Samantha L. Hocking, David E. James

1 April 2013 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
JKJames Robert Krycer
James Robert Krycer
ABAndrew John Brown
Andrew John Brown

1 June 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JKJames Robert Krycer
James Robert Krycer
ABAndrew John Brown
Andrew John Brown
High cholesterol levels are associated with prostate cancer development. Androgens promote cholesterol accumulation by activating the sterol-regulatory element-binding protein isoform 2 (SREBP-2) transcription factor. However, SREBP-2 is in balance with the liver X receptor (LXR; NR1H2/NR1H3), a transcription factor that prevents cholesterol accumulation. Here, we show that LXR activity is down-regulated by the androgen receptor (AR; NR3C4). In turn, this reduces LXR target gene expression. This antagonism on LXR is also exerted by other steroid hormone receptors, including the estrogen, glucocorticoid, and progesterone receptors. This suggests a generalizable mechanism, but the AR does not affect LXR mRNA levels, protein degradation, or DNA binding. We also found that the AR does not require protein synthesis to influence LXR, suggesting a direct antagonism. However, the AR does not directly bind LXR. The AR N-terminal domain (involved in transactivation), but not its DNA-binding domain, is required to suppress LXR activity, suggesting coactivator competition. Overall, this androgen-mediated antagonism of LXR complements SREBP-2 activation, providing a more complete picture as to how androgens increase cellular cholesterol levels in a prostate cancer setting. Given the cross-talk between other steroid hormone receptors and LXR, hormonal regulation of cholesterol via LXR may occur in a variety of cellular contexts.

1 September 2014 in Molecular Metabolism
Verified
Journal Article
Open access
MKMaximilian Kleinert
Maximilian Kleinert
LSLykke Sylow
Lykke Sylow
DFDaniel Fazakerley
Daniel Fazakerley
JKJames R. Krycer
James R. Krycer
KTKristen C. Thomas
Kristen C. Thomas
ERErik A. Richter
Erik A. Richter
The effect of acute inhibition of both mTORC1 and mTORC2 on metabolism is unknown. A single injection of the mTOR kinase inhibitor, AZD8055, induced a transient, yet marked increase in fat oxidation and insulin resistance in mice, whereas the mTORC1 inhibitor rapamycin had no effect. AZD8055, but not rapamycin reduced insulin-stimulated glucose uptake into incubated muscles, despite normal GLUT4 translocation in muscle cells. AZD8055 inhibited glycolysis in MEF cells. Abrogation of mTORC2 activity by SIN1 deletion impaired glycolysis and AZD8055 had no effect in SIN1 KO MEFs. Re-expression of wildtype SIN1 rescued glycolysis. Glucose intolerance following AZD8055 administration was absent in mice lacking the mTORC2 subunit Rictor in muscle, and in vivo glucose uptake into Rictor-deficient muscle was reduced despite normal Akt activity. Taken together, acute mTOR inhibition is detrimental to glucose homeostasis in part by blocking muscle mTORC2, indicating its importance in muscle metabolism in vivo.